A Study of Ketamine as an Antidepressant

Status Recruiting

Clinical Trial Summary

Recently, interest has emerged in the use of ketamine as an antidepressant. Recent placebo-controlled clinical trials administering a single dose and an open label trial giving repeated doses shown that ketamine is markedly superior to placebo at reducing depression, including in treatment-resistant patients, and that its antidepressant effects have a very rapid onset.

This clinical study consists of two phases. In Phase I, participants who satisfy inclusion criteria will receive ketamine at variable doses (0.1mg/kg-0.5mg/kg) or a placebo (saline, or 0.01mg/kg midazolam) once a week over up to 6 weeks. If participants qualify for Phase II, they will receive repeated sessions of ketamine at variable doses over three weeks. During both phases, mood, psychiatric, and neuropsychological outcomes will be measured.

Clinical Trial Description

This clinical study consists of two phases. In Phase I, participants will receive variable doses of intravenous, intramuscular, or subcutaneous ketamine (0.1-0.5mg/kg) or placebo (saline, or 0.01mg/kg midazolam) weekly for up to 6 consecutive weeks. Prior to receiving ketamine/placebo, participants' mood and psychiatric symptoms will be assessed. Once they have received their treatment, mood, psychiatric side effects, ketamine blood levels, heart rate, blood pressure and biomarkers will be assessed. Mood and cognitive performance be assessed again after 4 hours. Finally, mood will also be assessed the next day.

Some participants may be eligible to continue to Phase II. In this phase, participants will receive doses of ketamine approximately weekly for up to 6 months. During this phase, participants' mood, psychiatric, biomarkers and cognitive outcomes will be assessed.

The purpose of the trial is to investigate the antidepressant and safety effects of using ketamine as a treatment in depression. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01441505
Study type	Interventional
Source	The University of New South Wales
Contact	Angelo Alonzo
Phone	61 02 9382 3720
Email	TMSandDCS@unsw.edu.au
Status	Recruiting
Phase	Phase 2
Start date	September 2011
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03256162` - Ketamine as an Adjunctive Therapy for Major Depression	Phase 1
Completed	`NCT01944293` - Ketamine for Suicidality in Bipolar Depression	Phase 1/Phase 2
Active, not recruiting	`NCT03487926` - Microglial Activation in Inflammatory Bowel Disease
Recruiting	`NCT04939649` - Ketamine as an Adjunctive Therapy for Major Depression (2)	Phase 3
Recruiting	`NCT05028738` - Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety	N/A
Recruiting	`NCT03646058` - Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode	Phase 3
Not yet recruiting	`NCT06117397` - A Text Messaging Intervention to Reduce Perinatal Depression Risk	N/A
Completed	`NCT03735576` - Cognitive Behavioural Therapy for the Treatment of Late Life Depression	N/A
Recruiting	`NCT04999553` - Left vs. Right Non-Inferiority Trial	N/A
Completed	`NCT03716869` - Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder	N/A
Recruiting	`NCT02824081` - Neuroinflammation, Serotonin, Impulsivity and Suicide	N/A
Terminated	`NCT01099592` - Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression	Phase 4
Completed	`NCT03752853` - Stress Systems and Psychotherapy in Depression	N/A
Recruiting	`NCT04480918` - University of Iowa Interventional Psychiatry Service Patient Registry
Recruiting	`NCT04130958` - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics	N/A
Completed	`NCT03190772` - The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation	N/A
Recruiting	`NCT04832750` - Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep
Terminated	`NCT02839798` - NeoSync TMS Treatment for Bipolar I Depression	Phase 2
Completed	`NCT00852592` - Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial	Phase 3
Terminated	`NCT05063604` - Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.